{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:14:42Z","timestamp":1791976482677,"version":"4.4.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Gastroenterol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s12664-023-01384-2","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T11:01:58Z","timestamp":1688727718000},"page":"475-484","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Vonoprazan versus lansoprazole in erosive esophagitis \u2014 A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"42","author":[{"given":"Saurabh","family":"Chandan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smit","family":"Deliwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babu P.","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl","family":"Ramai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banreet","family":"Dhindsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Bapaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena L.","family":"Kassab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ojasvini Choudhry","family":"Chandan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Facciorusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas G.","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,7]]},"reference":[{"issue":"3","key":"1384_CR1","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1136\/gutjnl-2016-313589","volume":"67","author":"LH Eusebi","year":"2018","unstructured":"Eusebi LH, Ratnakumaran R, Yuan Y, et al. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut. 2018;67:430\u201340.","journal-title":"Gut."},{"issue":"5","key":"1384_CR2","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1053\/j.gastro.2019.12.014","volume":"158","author":"SD Delshad","year":"2020","unstructured":"Delshad SD, Almario CV, Chey WD, Spiegel BMR. Prevalence of gastroesophageal reflux disease and proton pump inhibitor-refractory symptoms. Gastroenterology. 2020;158:1250\u201361.e2.","journal-title":"Gastroenterology."},{"issue":"8","key":"1384_CR3","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1155\/1998\/925346","volume":"12","author":"AB Thomson","year":"1998","unstructured":"Thomson AB, Chiba N, Armstrong D, et al. The second Canadian gastroesophageal reflux disease consensus: moving forward to new concepts. Can J Gastroenterol. 1998;12:551\u20136.","journal-title":"Can J Gastroenterol."},{"issue":"39","key":"1384_CR4","doi-asserted-by":"crossref","first-page":"8831","DOI":"10.3748\/wjg.v22.i39.8831","volume":"22","author":"H Moole","year":"2016","unstructured":"Moole H, Patel J, Ahmed Z, et al. Progression from low-grade dysplasia to malignancy in patients with Barrett\u2019s esophagus diagnosed by two or more pathologists. World J Gastroenterol. 2016;22:8831\u201343.","journal-title":"World J Gastroenterol."},{"issue":"6","key":"1384_CR5","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.pathol.2021.06.116","volume":"53","author":"EH Tsoi","year":"2021","unstructured":"Tsoi EH, Williams RA, Christie M, et al. Not all low grade dysplasia in Barrett\u2019s oesophagus is the same: using specific histological criteria in predicting progression to neoplasia. Pathology. 2021;53:700\u20134.","journal-title":"Pathology."},{"issue":"10","key":"1384_CR6","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/17474124.2022.2134115","volume":"16","author":"R Yadlapati","year":"2022","unstructured":"Yadlapati R, Hubscher E, Pelletier C, et al. Induction and maintenance of healing in erosive esophagitis in the United States. Expert Rev Gastroenterol Hepatol. 2022;16:967\u201380.","journal-title":"Expert Rev Gastroenterol Hepatol."},{"issue":"1","key":"1384_CR7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14309\/ajg.0000000000001538","volume":"117","author":"PO Katz","year":"2022","unstructured":"Katz PO, Dunbar KB, Schnoll-Sussman FH, et al. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2022;117:27\u201356.","journal-title":"Am J Gastroenterol."},{"issue":"6","key":"1384_CR8","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.gie.2015.02.021","volume":"81","author":"VR Muthusamy","year":"2015","unstructured":"Muthusamy VR, Lightdale JR, Acosta RD, et al. The role of endoscopy in the management of GERD. Gastrointest Endosc. 2015;81:1305\u201310.","journal-title":"Gastrointest Endosc."},{"issue":"13","key":"1384_CR9","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.2169\/internalmedicine.52.0349","volume":"52","author":"K Higuchi","year":"2013","unstructured":"Higuchi K, Joh T, Nakada K, Haruma K. Is proton pump inhibitor therapy for reflux esophagitis sufficient?: a large real-world survey of Japanese patients. Intern Med. 2013;52:1447\u201354.","journal-title":"Intern Med."},{"issue":"3","key":"1384_CR10","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1572-0241.2001.03600.x","volume":"96","author":"JE Richter","year":"2001","unstructured":"Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol. 2001;96:656\u201365.","journal-title":"Am J Gastroenterol."},{"issue":"7","key":"1384_CR11","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/apt.16295","volume":"53","author":"Y Abdel-Aziz","year":"2021","unstructured":"Abdel-Aziz Y, Metz DC, Howden CW. Review article: potassium-competitive acid blockers for the treatment of acid-related disorders. Aliment Pharmacol Ther. 2021;53:794\u2013809.","journal-title":"Aliment Pharmacol Ther."},{"issue":"7","key":"1384_CR12","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.14309\/ajg.0000000000001735","volume":"117","author":"L Laine","year":"2022","unstructured":"Laine L, Sharma P, Mulford DJ, et al. Pharmacodynamics and pharmacokinetics of the potassium-competitive acid blocker vonoprazan and the proton pump inhibitor lansoprazole in US subjects. Am J Gastroenterol. 2022;117:1158\u201361.","journal-title":"Am J Gastroenterol."},{"issue":"11","key":"1384_CR13","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.3390\/pharmaceutics14112538","volume":"14","author":"D Benedetto Tiz","year":"2022","unstructured":"Benedetto Tiz D, Bagnoli L, Rosati O, et al. FDA-approved small molecules in 2022: clinical uses and their synthesis. Pharmaceutics. 2022;14:2538.","journal-title":"Pharmaceutics."},{"issue":"8","key":"1384_CR14","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1007\/s00535-019-01572-y","volume":"54","author":"H Miwa","year":"2019","unstructured":"Miwa H, Igarashi A, Teng L, et al. Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease. J Gastroenterol. 2019;54:718\u201329.","journal-title":"J Gastroenterol."},{"issue":"47","key":"1384_CR15","doi-asserted-by":"crossref","first-page":"e31807","DOI":"10.1097\/MD.0000000000031807","volume":"101","author":"S Yang","year":"2022","unstructured":"Yang S, Deng W, Xie Z, Chen J. Efficacy and safety of proton pump inhibitors versus vonoprazan in treatment of erosive esophagitis: a PRISMA-compliant systematic review and network meta-analysis. Medicine (Baltimore). 2022;101:e31807.","journal-title":"Medicine (Baltimore)."},{"key":"1384_CR16","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ."},{"key":"1384_CR17","doi-asserted-by":"crossref","unstructured":"Mohan BP, Chandan S, Siau K. Young GI angle: How to learn & conduct meta-analysis: Tips & tricks for the emerging researcher. United European. Gastroenterol J. 2022;10:1031.","DOI":"10.1002\/ueg2.12322"},{"issue":"13","key":"1384_CR18","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1002\/1097-0258(20000715)19:13<1707::AID-SIM491>3.0.CO;2-P","volume":"19","author":"EA Engels","year":"2000","unstructured":"Engels EA, Schmid CH, Terrin N, et al. Heterogeneity and statistical significance in meta-analysis: an empirical study of 125 meta-analyses. Stat Med. 2000;19:1707\u201328.","journal-title":"Stat Med."},{"issue":"1","key":"1384_CR19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1472-6963-4-38","volume":"4","author":"D Atkins","year":"2004","unstructured":"Atkins D, Eccles M, Flottorp S, et al. Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv Res. 2004;4:38.","journal-title":"BMC Health Serv Res."},{"issue":"3","key":"1384_CR20","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u201388.","journal-title":"Control Clin Trials."},{"issue":"7414","key":"1384_CR21","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ."},{"key":"1384_CR22","unstructured":"Sutton AJ, Abrams KR,\u00a0 Jones DR, Sheldon TA,\u00a0 Song F.\u00a0Methods for Meta-Analysis in Medical Research. New York: J. Wiley; 2000."},{"issue":"4","key":"1384_CR23","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.gie.2018.10.036","volume":"89","author":"BP Mohan","year":"2019","unstructured":"Mohan BP, Adler DG. Heterogeneity in systematic review and meta-analysis: how to read between the numbers. Gastrointest Endosc. 2019;89:902\u20133.","journal-title":"Gastrointest Endosc."},{"issue":"2","key":"1384_CR24","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","volume":"56","author":"S Duval","year":"2000","unstructured":"Duval S, Tweedie R. Trim and fill: a simple funnel-plot\u2013based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455\u201363.","journal-title":"Biometrics."},{"issue":"6","key":"1384_CR25","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/apt.13331","volume":"42","author":"K Ashida","year":"2015","unstructured":"Ashida K, Sakurai Y, Nishimura A, et al. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther. 2015;42:685\u201395.","journal-title":"Aliment Pharmacol Ther."},{"issue":"2","key":"1384_CR26","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/apt.13461","volume":"43","author":"K Ashida","year":"2016","unstructured":"Ashida K, Sakurai Y, Hori T, et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 2016;43:240\u201351.","journal-title":"Aliment Pharmacol Ther."},{"issue":"2","key":"1384_CR27","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/gutjnl-2019-318365","volume":"69","author":"Y Xiao","year":"2020","unstructured":"Xiao Y, Zhang S, Dai N, et al. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis. Gut. 2020;69:224\u201330.","journal-title":"Gut."},{"issue":"1","key":"1384_CR28","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1053\/j.gastro.2022.09.041","volume":"164","author":"L Laine","year":"2022","unstructured":"Laine L, DeVault K, Katz P, et al. Vonoprazan versus lansoprazole for healing and maintenance of healing of erosive esophagitis: a randomized trial. Gastroenterology. 2022;164:61\u201371.","journal-title":"Gastroenterology."},{"issue":"3","key":"1384_CR29","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1055\/a-1369-5274","volume":"53","author":"IM Gralnek","year":"2021","unstructured":"Gralnek IM, Stanley AJ, Morris AJ, et al. Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH): European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2021. Endoscopy. 2021;53:300\u201332.","journal-title":"Endoscopy."},{"issue":"8","key":"1384_CR30","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.14309\/ajg.0000000000001788","volume":"117","author":"NJ Shaheen","year":"2022","unstructured":"Shaheen NJ, Falk GW, Iyer PG, et al. Guideline to practice: diagnosis and management of Barrett\u2019s esophagus: an updated ACG guideline. Am J Gastroenterol. 2022;117:1177\u201380.","journal-title":"Am J Gastroenterol."},{"issue":"5","key":"1384_CR31","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1007\/s10620-005-9071-3","volume":"51","author":"CJ Lightdale","year":"2006","unstructured":"Lightdale CJ, Schmitt C, Hwang C, Hamelin B. A multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (20 mg) and standard-dose omeprazole (20 mg) in patients with erosive esophagitis. Dig Dis Sci. 2006;51:852\u20137.","journal-title":"Dig Dis Sci."},{"issue":"36","key":"1384_CR32","doi-asserted-by":"crossref","first-page":"22438","DOI":"10.1074\/jbc.272.36.22438","volume":"272","author":"M Besancon","year":"1997","unstructured":"Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem. 1997;272:22438\u201346.","journal-title":"J Biol Chem."},{"key":"1384_CR33","doi-asserted-by":"crossref","first-page":"1756283X1774577","DOI":"10.1177\/1756283X17745776","volume":"11","author":"K Sugano","year":"2018","unstructured":"Sugano K. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date. Therap Adv Gastroenterol. 2018;11:1756283X17745776.","journal-title":"Therap Adv Gastroenterol."},{"issue":"1","key":"1384_CR34","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1124\/jpet.110.170274","volume":"335","author":"Y Hori","year":"2010","unstructured":"Hori Y, Imanishi A, Matsukawa J, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther. 2010;335:231\u20138.","journal-title":"J Pharmacol Exp Ther."},{"issue":"3","key":"1384_CR35","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1124\/jpet.111.179556","volume":"337","author":"Y Hori","year":"2011","unstructured":"Hori Y, Matsukawa J, Takeuchi T, et al. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals. J Pharmacol Exp Ther. 2011;337:797\u2013804.","journal-title":"J Pharmacol Exp Ther."},{"issue":"8","key":"1384_CR36","doi-asserted-by":"crossref","first-page":"480","DOI":"10.21037\/atm-22-1722","volume":"10","author":"Z Wang","year":"2022","unstructured":"Wang Z, Sun R, Sheng Y, et al. Cost-effectiveness analysis of vonoprazan versus proton pump inhibitors in the treatment of reflux esophagitis in China. Ann Transl Med. 2022;10:480.","journal-title":"Ann Transl Med."},{"issue":"17","key":"1384_CR37","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.2169\/internalmedicine.2535-18","volume":"58","author":"Y Habu","year":"2019","unstructured":"Habu Y. Vonoprazan versus lansoprazole for the initial treatment of reflux esophagitis: a cost-effectiveness analysis in Japan. Intern Med. 2019;58:2427\u201333.","journal-title":"Intern Med."},{"issue":"5","key":"1384_CR38","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/jgf2.429","volume":"22","author":"Y Habu","year":"2021","unstructured":"Habu Y, Hamasaki R, Maruo M, et al. Treatment strategies for reflux esophagitis including a potassium-competitive acid blocker: a cost-effectiveness analysis in Japan. J Gen Fam Med. 2021;22:237\u201345.","journal-title":"J Gen Fam Med."},{"issue":"2","key":"1384_CR39","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/apt.15062","volume":"49","author":"T Oshima","year":"2019","unstructured":"Oshima T, Arai E, Taki M, et al. Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis. Aliment Pharmacol Ther. 2019;49:140\u20136.","journal-title":"Aliment Pharmacol Ther."},{"issue":"6","key":"1384_CR40","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/MCG.0000000000001707","volume":"56","author":"T Oshima","year":"2022","unstructured":"Oshima T, Igarashi A, Nakano H, et al. Network meta-analysis comparing vonoprazan and proton pump inhibitors for heartburn symptoms in erosive esophagitis. J Clin Gastroenterol. 2022;56:493\u2013504.","journal-title":"J Clin Gastroenterol."},{"issue":"1","key":"1384_CR41","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10620-020-06141-5","volume":"66","author":"Y Cheng","year":"2021","unstructured":"Cheng Y, Liu J, Tan X, et al. Direct comparison of the efficacy and safety of vonoprazan versus proton-pump inhibitors for gastroesophageal reflux disease: a systematic review and meta-analysis. Dig Dis Sci. 2021;66:19\u201328.","journal-title":"Dig Dis Sci."},{"issue":"12","key":"1384_CR42","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1111\/jgh.16017","volume":"37","author":"DM Simadibrata","year":"2022","unstructured":"Simadibrata DM, Syam AF, Lee YY. A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2022;37:2217\u201328.","journal-title":"J Gastroenterol Hepatol."},{"issue":"8","key":"1384_CR43","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1111\/jgh.14664","volume":"34","author":"H Miyazaki","year":"2019","unstructured":"Miyazaki H, Igarashi A, Takeuchi T, et al. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: a systematic review. J Gastroenterol Hepatol. 2019;34:1316\u201328.","journal-title":"J Gastroenterol Hepatol."},{"key":"1384_CR44","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jclinepi.2019.03.003","volume":"110","author":"M Tsui","year":"2019","unstructured":"Tsui M, Rehal S, Jairath V, Kahan BC. Most noninferiority trials were not designed to preserve active comparator treatment effects. J Clin Epidemiol. 2019;110:82\u20139.","journal-title":"J Clin Epidemiol."},{"issue":"4","key":"1384_CR45","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1136\/gut.36.4.539","volume":"36","author":"EF Verd\u00fa","year":"1995","unstructured":"Verd\u00fa EF, Armstrong D, Fraser R, et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut. 1995;36:539\u201343.","journal-title":"Gut."}],"container-title":["Indian Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-023-01384-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12664-023-01384-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-023-01384-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T16:40:26Z","timestamp":1702744826000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12664-023-01384-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,7]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1384"],"URL":"https:\/\/doi.org\/10.1007\/s12664-023-01384-2","relation":{},"ISSN":["0254-8860","0975-0711"],"issn-type":[{"value":"0254-8860","type":"print"},{"value":"0975-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,7]]},"assertion":[{"value":"1 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study does not involve active human participants or animals. Therefore, formal consent, informed consent, institutional review board approval and ethical approval are not applicable and not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"This study does not involve active human participants or animals. Therefore, formal consent, informed consent, institutional review board approval and ethical approval are not applicable and not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics"}},{"value":"This study does not involve active human participants or animals. Therefore, formal consent, informed consent, institutional review board approval and ethical approval are not applicable and not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Douglas G Adler: consultant \u2014 Boston Scientific; SC, SD, BPM, DR, BD, JB, LLK, OCC\u00a0and AF\u00a0declare that they have no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors are solely responsible for the data and the content of the paper. In no way, the Honorary Editor-in-Chief, Editorial Board Members, the Indian Society of Gastroenterology or the printer\/publishers are responsible for the results\/ findings and content of this article.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}